Article Data

  • Views 2093
  • Dowloads 207

Meeting Abstracts

Open Access Special Issue

Approach of the relationship between fibromyalgia and bipolar disorder through an interesting case report

  • Eirini Chainaki11
  • Nektaria Polaki1
  • Dimitrios Manoukakis2

1Consultant Anaesthetist Venizeleio General Hospital, Heraklion, Greece

2Medical Director Anaesthetic Department Venizeleio General Hospital, Heraklion, Greece

DOI: 10.22514/sv.2021.174 Vol.17,Issue S1,September 2021 pp.29-29

Submitted: 26 August 2021 Accepted: 06 September 2021

Published: 15 September 2021

*Corresponding Author(s): Eirini Chainaki1 E-mail:


Introduction: 21% of patients suffering from fibromyalgia also suffer from bipolar disorder [1] and reversibly 50% of patients with bipolar disorder (BD) suffer from chronic pain syndromes including fibromyalgia [2]. Fibromyalgia and BD seem to share the same pathophysiologic mechanism [3]. The aim of this case report is to emphasize the interrelation of fibromyalgia and BD in order to improve the therapeutic management of those patients.

Method: A 45 years old female patient came into the Pain Clinic complaining about exacerbation of fibromyalgic pain for six months. She was receiving venflaxine 300 mg, Aripiprazole 10 mg, gabapentin 1800 mg, mirtazapine 30 mg daily. For analgesia she was taking a combination of paracetamol/ codeine in a daily dose of 4 gr/500 mg respectively and transdermal buprenorphine 70 μcg. Therapeutic interventions with trigger point injections and intra-articular injections on both knees was given. Past medical history: BD type II for 20 years, fibromyalgia for ten years, hypothyroidism. Social history: married with two children. She was working in administration of a public service. Physical examination: neck stiffness, tender points, WPI = 9 and SSS = 7, score on PHQ-9 questionnaire 20/27. Multivariant therapeutic approach: Adjustment of fibromyalgia pharmaceutical therapy. Communication with treating psychiatrist for modification of the therapy for BD. Complementary acupuncture therapy was provided. Evaluation of patient using VAS score and dose of analgesic medication on every session and three months after therapy. Questionnaire PHQ-9 was repeated at the end of therapy and three months afterwards.

Results: There was gradual reduction on the intensity of pain. The analgesic therapy was interrupted after the third session. PHQ-9 scored 5/27 at the end of therapy and 7/27 three months later.

Conclusions: Fibromyalgia and BD can coexist and the symptoms of one may shadow or worsen the symptoms of the other. Multivariant approach is needed for effective therapy and psychiatric intervention.

Cite and Share

Eirini Chainaki1,Nektaria Polaki,Dimitrios Manoukakis. Approach of the relationship between fibromyalgia and bipolar disorder through an interesting case report. Signa Vitae. 2021. 17(S1);29-29.


[1] Kudlow PA, Rosenblat JD, Weissman CR, Cha DS, Kakar R, McIntyre RS, et al. Prevalence of fibromyalgia and co-morbid bipolar disorder: A systematic review and meta-analysis. The Journal of Affective Disorders. 2015; 188: 134–142.

[2] Stubbs B, Eggermont L, Mitchell AJ, De Hert M, Correll CU, Soundy A, et al. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis. Acta Psychiatrica Scandinavica. 2015; 131: 75–88.

[3] Bortolato B, Berk M, Maes M, McIntyre RS, Carvalho AF. Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology. Current Molecular Medicine. 2016; 16: 119–136.

[4] Xia Y, Cao X, Wu G, Cheng J. Acupuncture Therapy For Neurological Diseases: A Neurobiological View. Springer Heidelberg Dordrecht: London New York. 2010

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time